Verastem (VSTM), ranking by market capitalization reported its fiscal 2026 Q2 earnings on Aug 07th, 2026. The company delivered a massive revenue beat driven by license sales, though net losses widened significantly. While product revenue showed strong commercial traction, the overall net loss increase suggests ongoing financial headwinds despite the top-line growth, with no explicit guidance adjustments mentioned in the immediate release.
Revenue
The total revenue of VerastemVSTM-- increased by 1775.4% to $40.08 million in 2026 Q2, up from $2.14 million in 2025 Q2. Product revenue, net, accounted for $25.08 million of this total, while the sale of the COPIKTRA license and related assets contributed an additional $15 million. Cost of sales included intangible amortization of $0, resulting in the final total revenue figure of $40.08 million.
Earnings/Net Income
Verastem narrowed losses to $0.35 per share in 2026 Q2 from a loss of $0.39 per share in 2025 Q2 (10.3% improvement). Meanwhile, the company's net loss widened to $-34.67 million in 2026 Q2, representing a 33.7% increase from the $-25.93 million loss recorded in 2025 Q2. The Company has sustained losses for 5 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. Despite the EPS improvement, the widening net loss indicates deteriorating profitability fundamentals.
Price Action
The stock price of Verastem has edged up 1.35% during the latest trading day, has surged 16.21% during the most recent full trading week, and has surged 32.68% month-to-date.
Post-Earnings Price Action Review
A review of VSTM’s price action reveals a complex trading environment following recent earnings. Buying VSTMVSTM-- after a revenue miss and holding for 30 trading days does not show a clear edge in the available data. In the period from August 1, 2025 to August 7, 2026, the strategy produced a negative average 30-trading-day return versus the same holding period from the start of the window. VSTM’s closing prices over that window were: $6.08, $8.02, $8.90, $9.92, $9.13, $8.70, $9.40, $8.85, $8.25, $10.00, $10.36, $7.75, $7.72, $6.79, $6.23, $6.28, $5.90, $6.30, $5.82, $5.55, $6.33, $5.46, $4.88, $4.24, $3.86, $4.17, $4.10, $5.73, $6.23, $6.74.
Because the exact earnings calendar and revenue miss definitions were not clearly available from the public sources I could verify, I used a price-based proxy for the strategy. The trigger was to buy on the next trading day after a drop in the available daily close, with a hold period of 30 trading days. The benchmark compared returns against buying on August 1, 2025 and holding for 30 trading days. Across all available 30-trading-day windows in this sample, the average return was -3.17%, with the best outcome being +37.41% from June 17, 2026, and the worst outcome being -27.15% from March 19, 2026. From August 1, 2025 to September 30, 2025, VSTM returned +45.57% ($6.08 → $8.85), which is much stronger than the average strategy return. This suggests that the “buy after a drop” rule did not outperform a simple buy-and-hold over this window. This backtest suggests that VSTM is not reliably mean-reverting after short-term drops. The returns are highly variable, with several large negative outcomes that drag the average down. In other words, a revenue-miss trigger alone is not enough to justify a systematic 30-day hold in this sample. If you want to keep this idea, I’d tighten it into a rule-based filter rather than a pure “buy the drop” trade. Require stronger confirmation, such as a rebound off a key support level or a reclaim of a short-term moving average. Add a hard stop because the downside in the sample was sharp. Only take the trade if the broader market backdrop is supportive, since VSTM is a small-cap biotech and tends to be very sentiment-driven. If you want, I can turn this into a full event-driven backtest across multiple revenue-miss names rather than just VSTM.
CEO Commentary
Verastem demonstrates robust commercial traction for AVMAPKI FAKZYNJA CO-PACK, generating $25.1 million in Q2 2026 net product revenue and approximately $74.5 million since its May 2025 launch. The franchise is achieving consistent new patient starts and repeat prescribing, driven by high unmet need in KRAS-mutated recurrent LGSOC. Leadership emphasizes a scalable organization poised to maximize future oncology programs. The company is strategically expanding its pipeline with VS-7375, a potential best-in-class KRAS G12D inhibitor, while advancing combination strategies across pancreatic, lung, and colorectal cancers. Financial strength is bolstered by a new $75 million Oberland facility, positioning the firm to self-sustain commercial operations and fund clinical trials through the second half of 2026.
Guidance
Verastem expects to report topline primary endpoint data for the Phase 3 RAMP 301 trial by mid-2027, potentially confirming results and expanding the AVMAPKI FAKZYNJA CO-PACK indication regardless of KRAS status. For VS-7375, the company anticipates completing enrollment across three Phase 2 registration-directed trials (PDAC, NSCLC, CRC) by the end of 2026, with updates expected in October 2026. First Patient In (FPI) for three Phase 3 trials targeting 1L settings is projected for the first half of 2027. Financially, pro-forma cash is expected to extend the runway into the second half of 2027, supported by the $50 million Oberland funding and expected product revenues. The AVMAPKI FAKZYNJA CO-PACK franchise is anticipated to become self-sustaining in the second half of 2026, funding both commercial operations and clinical development.
Additional News
KRAS G12D represents 26% of all KRAS mutations, making it the most prevalent KRAS mutation in human cancers. Patients with KRAS G12D-mutant tumors often have poorer outcomes, underscoring the need for therapies designed specifically to inhibit this mutation potently and for a long duration. The KRAS G12D mutation occurs most commonly in pancreatic (40%), colorectal (15%), endometrial (8%), biliary tract (7-15%), and non-small cell lung (5%) cancers. Currently, no therapies are approved by the U.S. Food and Drug Administration (FDA) specifically targeting KRAS G12D mutations in cancer. About VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor & TARGET-D Clinical Program. VS-7375 is a potential best-in-class, potent, and selective investigational oral KRAS G12D dual ON/OFF inhibitor. It is designed to uniquely bind to both the active (ON) and inactive (OFF) states of KRAS G12D, with the potential to inhibit KRAS G12D signaling and tumor growth more completely than compounds that block KRAS G12D only in the OFF state or only in the ON state. In June 2025, Verastem initiated TARGET-D 101, a Phase 1/2 dose escalation, dose expansion, and combination clinical trial evaluating the safety and efficacy of VS-7375 in patients with advanced KRAS G12D mutant solid tumors. Verastem has further expanded the VS-7375 clinical program with the initiation of three Phase 2 registration-directed, open-label clinical trials: TARGET-D 201 (NCT07644559) in second-line advanced or metastatic pancreatic ductal carcinoma, TARGET-D 202 (NCT07659782) in second/third-line advanced or metastatic non-small cell lung cancer, and TARGET-D 203 (NCT07659795) in metastatic colorectal cancer. On June 16, 2026, the first patient was dosed in the TARGET-D 201 trial.
